Gottschalk, Stephen

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,004

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021) · Science Translational Medicine

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 349

Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1

Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S. J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019) · New England Journal of Medicine

Virus-based gene therapy researchImmunodeficiency and Autoimmune Disorders

Cited by 263

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 215

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

Bollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 181

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 114

A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function

Lange, S., Sand, L. G. L., Bell, M., Patil, S. L., Langfitt, D., & Gottschalk, S. (2021) · Cancer Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 68

Is cancer gene therapy an empty suit?

Brenner, M. K., Gottschalk, S., Leen, A. M., & Vera, J. F. (2013) · The Lancet Oncology

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 52

Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours

Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B. (2021) · Cancer Gene Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 51

Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s

DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 12